A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms.
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Chromogranin A
/ metabolism
Female
Humans
Male
Middle Aged
Neural Cell Adhesion Molecules
/ metabolism
Neuroendocrine Tumors
/ pathology
Pancreatic Neoplasms
/ pathology
Prognosis
Progression-Free Survival
Retrospective Studies
Risk Factors
Survival Rate
Synaptophysin
/ metabolism
Young Adult
CD56
NCAM
Pancreatic neuroendocrine neoplasms
Simple index
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
27
01
2019
accepted:
08
03
2019
pubmed:
14
3
2019
medline:
17
6
2020
entrez:
14
3
2019
Statut:
ppublish
Résumé
The prognostic importance of the neuroendocrine (NE) markers involving neural cell adhesion molecule (NCAM) has been unclear enough to be adopted for WHO classification in patients with pancreatic neuroendocrine neoplasms (Pan-NENs). This study aimed to elucidate whether the three NE markers such as chromogranin A, synaptophysin, and NCAM decide prognoses for patients with well-differentiated tumors. Between April 2002 and October 2018, 217 patients were included in this study. Tissue samples from tumors of Pan-NENs were immunochemically stained for the aforementioned NE markers. Diffuse and intense staining was defined as positive, while faint or focal staining and non-staining were considered negative. The median age of patients was 55 years. The median observation period was 1415 days. In multivariate analysis of progression-free survival (PFS), liver metastasis, Ki-67 index, and triple-positive staining of NE markers were risk factors. The 5-year PFS rate of patients with and without triple-positive NE markers was 56.3% and 23.8%, respectively (P < 0.0001). In multivariate analysis of overall survival (OS), R0 resection, Ki-67 index and triple-positive NE markers (hazard ratio 0.4, P = 0.02) were the risk factors. The 5-year OS rate of patients with and without triple-positive NE markers was 88.8% and 66.4%, respectively (P = 0.014). The tumors of patients without triple-positive NE markers were associated with large tumor size, a high mitotic rate and high Ki-67 index. Triple-positive NE marker staining was a simple and practical indicator of prognoses in patients with well-differentiated Pan-NETs.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic importance of the neuroendocrine (NE) markers involving neural cell adhesion molecule (NCAM) has been unclear enough to be adopted for WHO classification in patients with pancreatic neuroendocrine neoplasms (Pan-NENs). This study aimed to elucidate whether the three NE markers such as chromogranin A, synaptophysin, and NCAM decide prognoses for patients with well-differentiated tumors.
METHODS
METHODS
Between April 2002 and October 2018, 217 patients were included in this study. Tissue samples from tumors of Pan-NENs were immunochemically stained for the aforementioned NE markers. Diffuse and intense staining was defined as positive, while faint or focal staining and non-staining were considered negative.
RESULTS
RESULTS
The median age of patients was 55 years. The median observation period was 1415 days. In multivariate analysis of progression-free survival (PFS), liver metastasis, Ki-67 index, and triple-positive staining of NE markers were risk factors. The 5-year PFS rate of patients with and without triple-positive NE markers was 56.3% and 23.8%, respectively (P < 0.0001). In multivariate analysis of overall survival (OS), R0 resection, Ki-67 index and triple-positive NE markers (hazard ratio 0.4, P = 0.02) were the risk factors. The 5-year OS rate of patients with and without triple-positive NE markers was 88.8% and 66.4%, respectively (P = 0.014). The tumors of patients without triple-positive NE markers were associated with large tumor size, a high mitotic rate and high Ki-67 index.
CONCLUSIONS
CONCLUSIONS
Triple-positive NE marker staining was a simple and practical indicator of prognoses in patients with well-differentiated Pan-NETs.
Identifiants
pubmed: 30863885
doi: 10.1007/s00535-019-01570-0
pii: 10.1007/s00535-019-01570-0
doi:
Substances chimiques
Biomarkers, Tumor
0
CHGA protein, human
0
Chromogranin A
0
Neural Cell Adhesion Molecules
0
SYP protein, human
0
Synaptophysin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-828Subventions
Organisme : Grant-in-Aid for Scientific Research (C)
ID : 15K10046
Références
J Clin Oncol. 2002 Jun 1;20(11):2633-42
pubmed: 12039924
Cancer. 2003 Aug 25;99(4):240-6
pubmed: 12925986
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73
pubmed: 16030115
Ann Surg. 2007 Feb;245(2):273-81
pubmed: 17245182
J Clin Oncol. 2007 Dec 10;25(35):5609-15
pubmed: 18065733
Ann Surg. 2008 Mar;247(3):490-500
pubmed: 18376195
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Am J Pathol. 1991 Aug;139(2):275-86
pubmed: 1867319
Dig Dis Sci. 1991 Jul;36(7):933-42
pubmed: 2070707
Am J Surg Pathol. 2012 Feb;36(2):173-84
pubmed: 22251937
Ann Surg. 2012 Aug;256(2):321-5
pubmed: 22415420
Surgery. 2012 Jul;152(1):107-13
pubmed: 22503317
J Natl Cancer Inst. 2012 May 16;104(10):764-77
pubmed: 22525418
J Surg Oncol. 2012 Nov;106(6):724-7
pubmed: 22549809
Pancreas. 2013 May;42(4):557-77
pubmed: 23591432
Lancet Oncol. 2014 Jan;15(1):e8-21
pubmed: 24384494
J Gastroenterol. 2015 Jan;50(1):58-64
pubmed: 24499825
Ann Surg Oncol. 2014 Oct;21(11):3515-21
pubmed: 24841347
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Ann Thorac Surg. 2015 Mar;99(3):983-9
pubmed: 25596870
Am J Surg Pathol. 2015 May;39(5):683-90
pubmed: 25723112
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Surgery. 2017 May;161(5):1235-1245
pubmed: 28111046
Clin Cancer Res. 2017 Aug 15;23(16):4625-4632
pubmed: 28455360
Ann Surg. 2018 Jun;267(6):1148-1154
pubmed: 28594340
Ann Surg Oncol. 2018 Aug;25(8):2467-2474
pubmed: 29789972
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702
pubmed: 29891520
Ann Surg. 2018 Jul 3;:null
pubmed: 29979246